Accepted abstracts for Oral Podium and Quickshot presentations at the 2026 International Invasive Lobular Carcinoma Symposium.
All accepted abstracts from oral and poster presentations will be published in the journal of Breast Cancer Research and Treatment.
Presentation
First Name
Last Name
Institution or Affiliation
Abstract Title
Podium
Christopher
Merkel
University of Pittsburgh
AP-2β Defines a Mammary Epithelial Subpopulation With a Potential Role in Lobular Carcinoma Initiation
Podium
Anna
Vertido
University of California, San Francisco
Incidence of bilateral breast cancer in patients with invasive lobular carcinoma of the breast: an institutional cohort study of 998 patients
Podium
Jason
Mouabbi
UT MD Anderson
IvoLoC: A Phase II Trial of Ivonescimab (IVO) in Endocrine-Refractory Hormone Receptor (HR)–Positive or Triple-Negative (TN) metastatic Invasive Lobular Carcinoma (mILC)
Podium
Higinio
Dopeso
Memorial Sloan Kettering Cancer Center
Context-dependent tumor suppressor role of RHOA in breast cancer through cooperation with CDH1 loss
Podium
Renee
Flaherty
City St George’s, University of London, The Institute of Cancer Research
Multimodal analysis of tumour evolution in ILC reveals dynamic changes in extracellular matrix
Podium
Elleke
Dresen
University Hospitals Leuven
The accuracy of whole-body diffusion-weighted MRI in the staging of invasive lobular breast carcinoma: a retrospective study
Podium
Eduardo
Pena
King’s College London
The tumour microenvironment as source for prognostic biomarkers in invasive lobular breast cancer
Podium
Sumayya
Abdul Qadir
University of Toronto, The Hospital for Sick Children
Modeling recurrent ILC as a platform for the development of novel therapeutics
Quickshot
Julia
Ye
University of California, San Francisco
Beyond E-cadherin: Histologic and immunohistochemical features of invasive lobular carcinomas with non-truncating CDH1 mutations
Quickshot
Brent
Schlegel
Women’s Cancer Research Center, UPMC Hillman Cancer Center, Magee-Women’s Research Institute, University of Pittsburgh
PDOmics: Patient-Derived Organoids as a Multi-Omic Window into ILC Heterogeneity and Clinical Behavior
Quickshot
Amy
McCart Reed
The University of Queensland
LobSig, a prognostic biomarker set for ILC: where are we and why has it taken so long?
Quickshot
Melanie
Salvador
University of Colorado Anschutz, Colorado School of Public Health
Relative rates of ILC incidence in Colorado reflect socioeconomic or structural factors that may drive disparities in ILC diagnoses
Quickshot
Camille
Carette
Laboratory for Translational Breast Cancer Research, KU Leuven
Phenotypic characterization of tumor cells across non-blood body fluids from patients with metastatic invasive lobular breast cancer (ILC) and invasive breast cancer of no special type (IBC-NST)
Quickshot
Darcie
Seachrist
Cleveland Clinic, Case Western Reserve University
Focal Adhesion Dependencies in CDH1-deficient Lobular Breast Cancer
Quickshot
Chamil
Jinadasa
University of Wisconsin, Madison
Clinical Utility and Management Impact of 18F-FES PET/CT for Lobular Breast Cancer
Quickshot
Marni
McClure
Stanford University, National Cancer Institute
Spatial ecotypes within hormone-positive invasive lobular carcinoma uncover distinct immune microenvironment from invasive ductal carcinoma
Quickshot
Rachel
Brough
The Institute of Cancer Research
Introducing an ILC Dependency Atlas
Quickshot
Elisabeth
Abeles
University of California, San Francisco, Beth Israel Deaconess Medical Center
Omission of axillary surgery in patients with invasive lobular carcinoma of the breast: rates of nodal involvement in clinically node negative patients and impact on recurrence in a single institution analysis
Quickshot
Richard
Barth
Dartmouth-Hitchcock Medical Center
Utilization of a Supine MRI-based Guidance System, The Breast Cancer LocatorTM, to Decrease Positive Margin Rates after Lumpectomy: an International Randomized Prospective Trial
Session and Debate Speakers
Wednesday, September 23, 2026
Opening of 2026 International Invasive Lobular Carcinoma Symposium: Welcome
Rita Mukhtar, MD Professor of Surgery, University of California San Francisco, Program Director of the UCSF Lobular Breast Cancer Research Program
Debate 1: Tumor morphology alone should be used to diagnose ILC
Fouad Boulos, MD Professor of Pathology and Immunology, University of Washington in St. Louis, Section Head of Breast Pathology
Stuart Schnitt, MD Associate Professor of Pathology, Harvard Medical School, Chief of Cancer Pathology, Beth Israel Deaconess Medical Center, Chief of Oncologic Pathology, Dana-Farber Institute
Anne Vincent-Salomon, MD, PhD Department Head of Pathology and Pole Coordinator of Pathology-Genomics and Immunology, Institut Curie
Scientific Session 1: Genetics, Risk, and Exposures
Cathrin Brisken, MD, PhD Associate Professor, Swiss Federal Institute of Technology Lausanne (EPFL), Professor at the Institute of Cancer Research London
Giovanni Corso, MD, PhD Associate Professor of General Surgery, European Institute of Oncology
Tari King, MD, FACS, FSSO, FASCO Associate Professor, Emory University School of Medicine, Chief Surgical Officer, Winship Cancer Institute
Mindy Goldman, MD Clinical Professor, Obstetrics and Gynecology, University of California, San Francisco, Chief Clinical Officer at Midi Health
Scientific Session 2: The ILC Cell and Microenvironment
Chip Petricoin, PhD Distinguished University Professor, George Mason University, Co-Director, Center for Applied Proteomics and Molecular Medicine
Rebecca Riggins, PhD Professor of Oncology, Georgetown University, Associate Director of Training and Education, Lombardi Comprehensive Cancer Center
Wayne Stallaert, PhD Assistant Professor, Department of Computational and Systems Biology, University of Pittsburgh, UPMC Hillman Cancer Center
Thursday, September 24, 2026
Scientific Session 3: Mechanisms of Metastasis
Chris Lord, PhD Professor, Cancer Genomics and Deputy Director, Breast Cancer Now Toby Robins Research Centre, Institute of Cancer Research, London
Jay Debnath,MD Distinguished Professor and Chair of Pathology, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center
Kevin Cheung, MD Associate Professor, Public Health Sciences, Fred Hutchinson Cancer Center
Valerie Weaver, PhD Professor, Director of the Center for Bioengineering and Tissue Regeneration, Department of Surgery, University of California, San Francisco
Debate 2: Cytotoxic chemotherapy is ineffective in patients with metastatic ILC
Rebecca Shatsky, MD Associate Professor of Medicine, Breast Medical Oncology Team Leader, Moores Cancer Center, University of California, San Diego
Sherry Shen, MD Clinical Investigator, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, Co-Director of MSK Lobular Breast Cancer Program
Scientific Session 4: Model Systems & Pathology
Adrian Lee, PhD Professor of Pharmacology & Chemical Biology, University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh Foundation Chair, Director, Institute for Precision Medicine
Lounes Djerroudi, MD, PhD Pathologist and Researcher, Institut Curie; Visiting Investigator, Memorial Sloan Kettering Cancer Center
Yi Li, PhD Professor, Department of Molecular and Cellular Biology, Lester & Sue Smith Breast Center, Baylor College of Medicine
Ruth Keri, PhD Professor, Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Associate Director for Basic Research, Case Comprehensive Cancer Center
Keynote Address 1: Hereditary CDH1 Mutations: The identification and evolution of a cancer syndrome
Parry Guilford, PhD Professor, University of Otago, Co-Founder, Pacific Edge Ltd.
Scientific Session 5: Diagnostics and Clinical Management
Jason Mouabbi, MD Assistant Professor of Medical Oncology, University of Texas MD Anderson Cancer Center, Chair, Lobular Breast Cancer Alliance
Karen Van Baelen, MD, PhD Postdoctoral Research Fellow, Laboratory for Translational Breast Cancer Research at KU Leuven
Priscilla McAuliffe, MD, PhD Assistant Professor, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center
Rachel Jankowitz, MD Associate Professor of Clinical Medicine, University of Pennsylvania, Director of the Rena Rowan Breast Center at Abramson Cancer Center
Ariella Hanker, PhD Associate Professor, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
François Richard,PhD Bioinformatics Researcher, Laboratory for Translational Breast Cancer Research, KU Leuven University
Patrick Derksen, PhD Professor of Experimental & Preclinical Oncology, University Medical Center Utrecht
Keynote Address 2: Novel approaches to screening and clinical trials for breast cancer: how to improve care for ILC
Laura Esserman, MD, MBA Director, Breast Care Center, University of California, San Francisco
Scientific Session 8: Advanced Imaging and Artificial Intelligence
Manisha Bahl, MD Associate Professor of Radiology, Harvard Medical School, Associate Medical Director of Quality for Breast Imaging, Mass General Brigham
Molly Hogan, MD Assistant Attending in Radiology, Memorial Sloan Kettering Cancer Center
Elleke Dresen, MD, PhD Assistant Professor, KU Leuven, Co-Leader of Imaging Working Group, European Lobular Breast Cancer Consortium
Dynami Foundation Leigh Pate Memorial Lecture
Steffi Oesterreich, PhD Professor, Univ of Pittsburgh, Co-Director, Women’s Cancer Research Center, Co-Leader Cancer Biology Program, UPMC HCC and MWRI
Scientific Session 9: SNMMI Special Session – Imaging in ILC
Gary Ulaner, MD,PhD James & Pamela Muzzy Endowed Chair of Molecular Imaging and Therapy, Hoag Family Cancer Institute, Professor, University of Southern California
Hannah Linden, MD Athena Distinguished Professor, Breast Cancer Research, University of Washington, Fred Hutchinson Cancer Center
Wenhui Zhou, MD, PhD Radiologist, University of Wisconsin School of Medicine and Public Health
David Mankoff, MD, PhD Matthew J. Wilson Professor & Vice-Chair for Research, Radiology Department, Perelman School of Medicine at the University of Pennsylvania
